GH

Global health sciences venture fund

North America, British Columbia, Canada, Vancouver

Description

The strength of the life science industry

Investor Profile

Global health sciences venture fund has made 9 investments, with 0 in the past 12 months and 22% as lead.

Stage Focus

  • Series C (33%)
  • Series A (22%)
  • Series B (22%)
  • Seed (11%)
  • Series D (11%)

Country Focus

  • United States (78%)
  • France (11%)
  • Spain (11%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Life Science
  • Health Care
  • Pharmaceutical
  • Medical
  • Genetics
  • Health Diagnostics
  • Medical Device
  • Information Technology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Global health sciences venture fund frequently co-invest with?

20/20 HealthCare Partners
North America, Massachusetts, United States, Auburndale
Co-Investments: 2
Droia Ventures
Europe, Luxembourg, Luxembourg, Luxembourg
Co-Investments: 1
Quark Venture
North America, British Columbia, Canada, Vancouver
Co-Investments: 5
GF Securities
Asia, Guangdong, China, Guangzhou
Co-Investments: 1
Medison
Asia, HaMerkaz, Israel, Petah Tiqva
Co-Investments: 2
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 2
AB
Asia, Tel Aviv, Israel, Herzliya
Co-Investments: 2
Pontifax
Asia, Tel Aviv, Israel, Herzliya
Co-Investments: 4
Partners Innovation Fund
North America, Massachusetts, United States, Boston
Co-Investments: 2
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 1

Which angels does Global health sciences venture fund often collaborate with?

PT
North America, California, United States, San Francisco
Shared Deals: 1

What are some of recent deals done by Global health sciences venture fund?

Variantyx

Framingham, Massachusetts, United States

Variantyx is a molecular diagnostics company specializing in advanced genetic testing and diagnostics.

BiotechnologyGeneticsHealth CareHealth DiagnosticsLife Science
Series CMar 15, 2021
Amount Raised: $20,000,000
CalciMedica

La Jolla, California, United States

CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.

Health CareInformation TechnologyLife Science
Series DMar 11, 2021
Amount Raised: $21,000,000
Keros Therapeutics

Lexington, Massachusetts, United States

Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Series CMar 4, 2020
Amount Raised: $56,000,000
EnClear Therapies

Cambridge, Massachusetts, United States

EnClear Therapies is a biotechnology company developing device-based therapies for the treatment of neurodegenerative disease

BiotechnologyTherapeutics
Series AFeb 19, 2020
Amount Raised: $10,000,000
Volastra Therapeutics

New York, New York, United States

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.

BiotechnologyLife ScienceMedical
SeedFeb 11, 2020
Amount Raised: $12,000,000
Eyevensys

Paris, Ile-de-France, France

Eyevensys creates ophthalmic therapeutic bio factories to sustainably treat major eye diseases.

BiotechnologyMedical DeviceTherapeutics
Series BJan 8, 2020
Amount Raised: $30,000,000
Keros Therapeutics

Lexington, Massachusetts, United States

Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Series BJan 8, 2019
Amount Raised: $23,000,000
SQZ Biotech

Watertown, Massachusetts, United States

SQZ Biotech features a cell engineering technology designed to deliver a diverse set of materials into patient cells.

BiotechnologyLife ScienceTherapeutics
Series CAug 8, 2018
Amount Raised: $72,000,000
ABAC Therapeutics

Barcelona, Catalonia, Spain

ABAC Therapeutics (ABAC) develops new targeted antibiotics for patients with severe infections.

BiotechnologyLife ScienceTherapeutics
Series AFeb 15, 2018
Amount Raised: $20,004,651